Patent ID: 8592477

Claim:
A pharmaceutical composition comprising at least 5% rotigotine polymorphic form (II) and at least one pharmaceutically acceptable excipient, wherein the rotigotine polymorphic form (II) is characterized by having at least one parameter selected from the group consisting of: an X-ray powder diffraction spectrum comprising at least one peak at the following °2θ angles (±0.2): 12.04, 13.68, 17.72, 19.01; a Raman spectrum comprising at least one peak at the following wave numbers (±3 cm −1 ): 226.2, 297.0, 363.9, 737.3, 847.3, 1018.7, 1354.3 cm −1 ; a DSC peak with a T onset at 97° C.±2° C. measured with a heating rate of 10°/min; and a melting point of 97° C.±2° C.